Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May;17(5):663–671. doi: 10.2215/CJN.11480821

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 by the American Society of Nephrology

PMC Copyright notice

Figure 3. — Effect of dapagliflozin on kidney uric acid handling. Uric acid levels at baseline and after 12 weeks of treatment with dapagliflozin or gliclazide. (A) Plasma uric acid levels during fasting conditions. (B) Plasma uric acid levels during hyperinsulinemic euglycemia. (C) Plasma uric acid levels during hyperglycemia. (D) Within-group change in plasma uric acid. (E) Fractional excretion of uric acid levels derived from 24-hour urine samples. (F) Fractional excretion of uric acid levels during hyperinsulinemic euglycemia. (G) Fractional excretion of uric acid levels during hyperglycemia. (H) Within-group change from baseline in fractional excretion of uric acid. Data are mean ± SD. NS, not significant.